Floatz logo

Amifostine

Pneumonitis

MedImmune LLCSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Pneumonitis cohort.

Asset / SponsorPhaseRating
Tocilizumab
National Cancer Institute (NCI)
Phase 2CCC
HUMAN IMMUNOGLOBULINS
ECOG-ACRIN Cancer Research Group
Phase 2CCC
Infliximab
ECOG-ACRIN Cancer Research Group
Phase 2CCC
PREDNISONE TABLETS
ECOG-ACRIN Cancer Research Group
Phase 2CCC
POLY(ACETYL, ARGINYL)GLUCOSAMINE (25000-50000 MW)
Synspira, Inc.
Phase 1CC

View all 11 →

Same molecule, other indications

Amifostine is also rated in:

cancer of unknown primary siteDormant
BBB
Indicative ·
75 / 100
View asset →
lung cancerDormant
BB
Indicative ·
66 / 100
View asset →
radiation injuryDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →